DRUG 21516 - Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)

Project: Research project

Project Details

StatusActive
Effective start/end date5/4/22 → 5/4/25

Funding

  • Parexel (Prot#21516 // Prot#21516)
  • Bayer HealthCare Pharmaceuticals, Inc. (Prot#21516 // Prot#21516)